IP Group (IPO) H2 2024 earnings summary

Executive summary

• Delivered GBP 183 million in profitable cash exits for 2024, outperforming a weak VC market, with standout exits including Featurespace's sale to Visa and other notable realizations from Centessa, Garrison, and Kymab Therapeutics.

• Accelerated share buyback program, retiring over 10% of shares and committing up to GBP 80 million, representing nearly 20% of market cap.

• Underlying NAV per share declined by 15% year-over-year, primarily due to fair value reductions in key holdings and market headwinds.

• Proactive cost reduction measures led to a 23% decrease in net overhead run rate by year-end.

• Significant private capital opportunity identified, with a focus on long-term value creation and building relationships with institutional investors.

Financial highlights

• Gross cash at year-end was GBP 285.6 million, up from GBP 226.9 million in FY23, with GBP 277 million as of the call.

• NAV at year-end was GBP 953 million (97.7p per share), down from GBP 1,190 million (114.8p per share) in FY23, a 15% reduction.

• Over GBP 183 million in proceeds from exits, about three times the GBP 63 million invested during the year.

• Buybacks totaled GBP 30 million in 2024, with a further GBP 50 million committed.

• Portfolio remains well funded, with 84% of equity and debt investments in companies valued over GBP 4 million.

Outlook and guidance

• Focus for 2025 is to return NAV per share to positive growth and continue delivering profitable cash exits.

• Line of sight on GBP 250 million in private portfolio exits by end of 2027.

• 50% of all 2025 realizations to be returned to shareholders, with ongoing review of capital allocation.

• Targeting further private scale-up capital, especially from Australia, and monitoring UK pension fund reforms for new opportunities.

• Over 35 commercial and technical milestones expected in 2025, including clinical trials, product launches, and funding rounds.